Match!
Tingbo Liang
Zhejiang University
205Publications
26H-index
2,834Citations
Publications 224
Newest
#1Jian Zhang (ZJU: Zhejiang University)H-Index: 19
#2Wen-Qiao Yu (ZJU: Zhejiang University)H-Index: 3
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 10 authors...
Source
#1Wen Chen (ZJU: Zhejiang University)H-Index: 1
#2Tao Ma (ZJU: Zhejiang University)H-Index: 13
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 8 authors...
Abstract Background The aim of this study was to systematically evaluate and determine those patients with hepatocellular carcinoma (HCC) that would benefit from the administration of postoperative adjuvant transarterial chemoembolization (PA-TACE). Methods PubMed, Embase and Cochrane Library were searched for randomized controlled trials (RCTs) and observational studies up to July 30, 2019. The outcome of Overall survival (OS) and disease-free survival (DFS) were extracted and converted to haza...
Source
#1Xiang Li (ZJU: Zhejiang University)H-Index: 3
#2Da-bing Huang (ZJU: Zhejiang University)
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 15 authors...
Abstract Objectives FOLFIRINOX (FFX) or abraxane plus gemcitabine (AG)-based chemotherapy is used widely as firstline treatment for patients with pancreatic cancer. However, their use in the elderly is discouraged because of adverse events. More clinical data about the therapeutic response and tolerability to FFX or AG in elderly patents (over 70 years old) are required. Methods Patients with advanced pancreatic cancer (n = 203; 131 metastatic pancreatic cancer patients (MPC) and 72 locally adva...
Source
#1Qida Hu (ZJU: Zhejiang University)H-Index: 17
#2Wangteng Wu (ZJU: Zhejiang University)
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 12 authors...
Abstract Malignancies treated by insoluble targeted agents show low dose exposure and therapeutic responses, therefore easily develop drug resistance. Nanoparticle-modified drugs might disrupt chemoresistance by increasing dose exposure and altering resistance pathways, as administrated via the intravenous route to maximize efficacy. Herein, we proposed a self-assembled nanocapsulation strategy to construct a nanocomplex with multiarm polymer and novel dendrimer series (MAP-mG3) for encapsulatin...
Source
#1Tao Ma (ZJU: Zhejiang University)H-Index: 13
#2Yibo Zhang (ZJU: Zhejiang University)H-Index: 1
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 10 authors...
Source
#1Tian-Yu Tang (ZJU: Zhejiang University)H-Index: 1
#2Xiang Li (ZJU: Zhejiang University)H-Index: 3
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 18 authors...
Source
#1Xing Huang (ZJU: Zhejiang University)H-Index: 3
#2Xiaozhen Zhang (ZJU: Zhejiang University)H-Index: 2
Last.Tingbo Liang (ZJU: Zhejiang University)H-Index: 26
view all 4 authors...
Source
#1Qi ZhangH-Index: 17
#2Yiwen ChenH-Index: 4
Last.Tingbo LiangH-Index: 26
view all 4 authors...
Source
#1Yi-Nan ShenH-Index: 2
#2Tian-Yu TangH-Index: 1
Last.Xueli BaiH-Index: 20
view all 8 authors...
Source
#1Qi ZhangH-Index: 17
#2Yu LouH-Index: 7
Last.Xueli BaiH-Index: 20
view all 25 authors...
Objective Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal tumours, which decreases the efficacy of clinical treatments. Understanding tumour heterogeneity is critical when developing novel treatment strategies. However, a comprehensive investigation of tumour heterogeneity in HCC is lacking, and the available evidence regarding tumour heterogeneity has not led to improvements in clinical practice. Design We harvested 42 samples from eight HCC patients and evaluated tumo...
4 CitationsSource
12345678910